• Home
  • About Us
    Our Approach Our Team Board
  • Pipeline
  • News
  • Honor
  • Careers
  • Collaboration
  • Investor Relations
    Disclosure Contact IR
  • Contact
中文 ENG
    • Home
    • About us
      • Our Approach
      • Our Team
      • Board
    • Pipeline
    • News
    • Honor
    • Careers
    • Collaboration
    • Investor Relations
      • Disclosure
      • Contact IR
    • Contact
    • CN

COMPANY NEWS

Category Company News Enterprise Honor
2025 08

14

TYK Medicines, Inc.’s EGFR-Targeted Innovative Drug Asandeutertinib Demonstrates Excellent Efficacy in NSCLC Patients with Brain Metastases — Interim Results from the ESAONA Pivotal Study Announced at WCLC 2025

Discover More
2025 04

24

Asandeutertinib (TY-9591) Submitted for Pre-New Drug Application

Discover More
2025 04

16

JTO Published Phase I Study Results of Asandeutertinib Mesylate Tablets

Discover More
2025 02

25

TYK Medicine’s CDK7 Inhibitor TY-2699a Receives CDE Clinical Approval for Combination Therapy

Discover More
2025 02

25

TYK Medicine’s CDK2 Inhibitor Receive Clinical Approval from CDE for Combination Therapy

Discover More
2024 09

06

The Results of Asandeutertinib Tablets (TY-9591) will be Presented at the WCLC 2024

Discover More
12345>
CN ENG
  • Home
  • About Us
  • Pipeline
  • News
  • Honor
  • Careers
  • Investors
  • Contact
Powered by SE

Copyright © 2019 浙江同源康 版权所有 浙ICP备19008464号